NADAC acquisition cost data for OXAZEPAM 10 MG CAPSULE. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00228206710 | $0.8254 | 2022-12-21 | Rx |
| 52817029010 | $0.8254 | 2022-12-21 | Rx |
| 62584081201 | $0.8254 | 2022-12-21 | Rx |
| 62584081211 | $0.8254 | 2022-12-21 | Rx |
| 00228206710 | $0.8254 | 2022-12-21 | Rx |
| 52817029010 | $0.8254 | 2022-12-21 | Rx |
| 62584081201 | $0.8254 | 2022-12-21 | Rx |
| 62584081211 | $0.8254 | 2022-12-21 | Rx |
Generic: Oxazepam | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $4.2M | 62,556 | 10,833 | $0.9948 |
| 2020 | $3.7M | 54,945 | 9,201 | $1.02 |
| 2021 | $3.2M | 48,580 | 8,217 | $1.01 |
| 2022 | $2.7M | 42,444 | 7,303 | $0.9770 |
| 2023 | $2.4M | 37,468 | 6,587 | $0.9685 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $287.0K | 5,490 | 1,126 |
| Pennsylvania | $243.3K | 3,538 | 619 |
| Massachusetts | $150.7K | 2,701 | 456 |
| Florida | $118.6K | 1,928 | 347 |
| Ohio | $108.7K | 1,645 | 292 |
| Texas | $104.7K | 1,459 | 279 |
| Michigan | $102.2K | 1,246 | 217 |
| Alabama | $78.3K | 1,206 | 199 |
| Kentucky | $75.9K | 1,272 | 186 |
| New York | $74.9K | 1,050 | 215 |
| Tennessee | $74.7K | 1,157 | 187 |
| North Carolina | $71.5K | 1,159 | 188 |
| Illinois | $67.6K | 906 | 170 |
| Georgia | $58.6K | 866 | 155 |
| Virginia | $57.6K | 979 | 204 |
| Indiana | $49.7K | 811 | 133 |
| South Carolina | $48.3K | 737 | 158 |
| New Jersey | $45.1K | 603 | 145 |
| Oregon | $36.0K | 814 | 187 |
| Maryland | $33.3K | 460 | 85 |
| Missouri | $33.2K | 541 | 99 |
| Wisconsin | $32.8K | 484 | 76 |
| West Virginia | $32.4K | 492 | 80 |
| Connecticut | $31.2K | 561 | 106 |
| Minnesota | $27.2K | 342 | 55 |
| Iowa | $23.8K | 363 | 54 |
| Arkansas | $23.5K | 296 | 52 |
| Arizona | $23.2K | 370 | 62 |
| Kansas | $23.2K | 413 | 77 |
| Maine | $22.7K | 425 | 61 |
| Colorado | $20.3K | 378 | 65 |
| New Hampshire | $19.1K | 306 | 60 |
| Washington | $17.9K | 365 | 94 |
| Oklahoma | $17.4K | 226 | 43 |
| Louisiana | $16.3K | 331 | 64 |
| Nevada | $14.9K | 173 | 29 |
| New Mexico | $11.6K | 165 | 27 |
| Nebraska | $11.2K | 155 | 28 |
| Vermont | $10.5K | 161 | 32 |
| Rhode Island | $9.6K | 168 | 47 |
| Mississippi | $9.3K | 133 | 24 |
| Puerto Rico | $7.5K | 134 | 18 |
| Delaware | $5.8K | 90 | 20 |
| Hawaii | $4.4K | 76 | N/A |
| Utah | $3.7K | 37 | 13 |
| Idaho | $3.0K | 72 | 17 |
| North Dakota | $2.6K | 43 | N/A |
| Alaska | $2.5K | 23 | N/A |
| Montana | $2.2K | 52 | 12 |
| District of Columbia | $2.0K | 37 | 12 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.